Marshall Financial Group Inc. ADV Has $2.76 Million Position in Johnson & Johnson (NYSE:JNJ)

Marshall Financial Group Inc. ADV lowered its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 0.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 15,557 shares of the company’s stock after selling 122 shares during the period. Johnson & Johnson accounts for 1.3% of Marshall Financial Group Inc. ADV’s portfolio, making the stock its 18th largest position. Marshall Financial Group Inc. ADV’s holdings in Johnson & Johnson were worth $2,762,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also modified their holdings of the company. RE Dickinson Investment Advisors LLC boosted its stake in Johnson & Johnson by 163.3% in the first quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock valued at $28,000 after acquiring an additional 98 shares during the last quarter. Morton Brown Family Wealth LLC boosted its stake in Johnson & Johnson by 78.0% in the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock valued at $32,000 after acquiring an additional 78 shares during the last quarter. Advanced Research Investment Solutions LLC boosted its stake in Johnson & Johnson by 200.0% in the first quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock valued at $32,000 after acquiring an additional 120 shares during the last quarter. Professional Financial Advisors LLC boosted its stake in Johnson & Johnson by 47.9% in the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock valued at $37,000 after acquiring an additional 68 shares during the last quarter. Finally, Goodman Advisory Group LLC bought a new position in shares of Johnson & Johnson during the second quarter worth $39,000. Institutional investors and hedge funds own 68.59% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other news, VP Peter Fasolo sold 22,864 shares of the business’s stock in a transaction dated Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the transaction, the vice president now directly owns 114,676 shares in the company, valued at approximately $18,864,202. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider William Hait sold 15,000 shares of the business’s stock in a transaction dated Monday, October 24th. The shares were sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the transaction, the insider now directly owns 80,236 shares in the company, valued at approximately $13,764,485.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Peter Fasolo sold 22,864 shares of the business’s stock in a transaction dated Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the transaction, the vice president now owns 114,676 shares in the company, valued at $18,864,202. The disclosure for this sale can be found here. Insiders have sold 118,795 shares of company stock worth $20,230,174 in the last ninety days. Insiders own 0.35% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of recent analyst reports. Raymond James reduced their price target on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 19th. Credit Suisse Group initiated coverage on shares of Johnson & Johnson in a research report on Thursday. They set a “neutral” rating and a $170.00 price target on the stock. Barclays initiated coverage on shares of Johnson & Johnson in a research report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price target on the stock. Atlantic Securities reduced their price target on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 19th. Finally, StockNews.com assumed coverage on shares of Johnson & Johnson in a research report on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Seven analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $181.33.

Johnson & Johnson Stock Up 0.8 %

Shares of JNJ stock opened at $176.20 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The firm’s fifty day moving average price is $167.84 and its two-hundred day moving average price is $171.35. The firm has a market capitalization of $460.67 billion, a P/E ratio of 24.54, a PEG ratio of 3.47 and a beta of 0.57.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.49 by $0.06. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The firm had revenue of $23.79 billion for the quarter, compared to analyst estimates of $23.44 billion. During the same period in the previous year, the business earned $2.60 EPS. The company’s revenue was up 1.9% compared to the same quarter last year. On average, equities analysts predict that Johnson & Johnson will post 10.04 EPS for the current fiscal year.

Johnson & Johnson declared that its Board of Directors has approved a share buyback plan on Wednesday, September 14th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 1.2% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its shares are undervalued.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Stockholders of record on Tuesday, November 22nd will be paid a dividend of $1.13 per share. The ex-dividend date of this dividend is Monday, November 21st. This represents a $4.52 annualized dividend and a dividend yield of 2.57%. Johnson & Johnson’s dividend payout ratio is presently 62.95%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.